www.horizonscan.nl gebruikt cookies om het gebruik van de website te analyseren en het gebruiksgemak te verbeteren. Lees meer over
cookies
op www.rijkshuisstijl.nl
Sluiten
You are here:
Horizonscan geneesmiddelen
Medicines
Search the site
Search
Published on
7 June 2022
Compact view
Extended view
Grouped by indication
Grouped by status
Grouped by reason of inclusion in Horizonscan Geneesmiddelen
Grouped by submission date
Grouped by expected registration date
Grouped by manufacturer
Grouped by mechanism of action
Grouped by particularity
Grouped by registration phase
Grouped by domain
Ungrouped
Filters
Sluit
Registration
Show ATMPs only
Show Orphan drugs only
Mechanism of action
Any mechanism of action
Unknown
Alkylating agent
Allergen
Allogeneic modified cell therapy
Amino acid
Anesthetic
Angiogenesis inhibitor
Antiandrogen
Antibiotic
Antibody-drug conjugate
Anticoagulant
Antifungals
Antihistamine
Antioxidant
Antisense oligonucleotide
Autologous modified cell therapy
Bcl-2 inhibitor
BET inhibitor
Calcineurin inhibitor
Cancer vaccine
Cannabinoid
CAR-T therapy
CDK4 / 6 tyrosine kinase inhibitor
CFS1R inhibitor
CGRP-directed antibody
Chelating agent
Coagulant
Combination therapy
Complement inhibitor
Corticosteroid
CTLA-4 antibody
Cytostatic
Disinfectant
Enzyme
Enzyme inhibitor
Enzyme replacement therapy
Gene therapy
GLP-1 receptor agonist
Glucagon analogue
Growth factor
HIV inhibitor
Hormonal therapy
Immunostimulation
Immunosuppression
Insulin preparation
Interferon inhibitor
Interleukin inhibitor
Ion channel blocker
JAK tyrosine kinase inhibitor
LABA / ICS
LABA / LAMA
LABA / LAMA / ICS
LAMA
MEK kinase inhibitor
Neurotoxin
Neurotransmitter
Oncolytic adenovirus
Other
Other, see general comments
PARP inhibitor
PD-1 / PD-L1 inhibitor
Proteasome inhibitor
Protein chaperone
Receptor agonist
Receptor antagonist
Serine / threonine kinase inhibitor
SGLT inhibitor
Small interfering RNA (siRNA)
Sodium channel blocker
Thrombin inhibitor
TNF-alpha inhibitor
Tyrosine kinase inhibitor
Vasodilator
Virus inhibitor
Budgetting framework
Any budgetting framework
Unknown
Extramural (GVS)
Intermural (MSZ)
Particularity
Any particularity
Unknown
New medicine with Priority Medicines (PRIME)
New therapeutical formulation
Reason of inclusion
New medicines
Indication extensions
IND
Biosimilars / generics
BS
G
Download
ADHD
Lisdexamfetamine
IND
Melatonine
Molindone
ALL
Brexucabtagene autoleucel
IND
Dasatinib
G
Obecabtagene autoleucel
Ponatinib
IND
ALS
Arimoclomol
IND
Sodium phenylbutyrate/tauroursodeoxycholic acid
AML / MDS
Azacitidine
Cytarabine / daunorubicin (liposomaal)
Decitabine/cedazuridine
Eprenetapopt
Glasdegib
Imetelstat
Iomab-B
Venetoclax
IND
Aggressive non-Hodgkin?s lymphoma
Axicabtagene ciloleucel
IND
Crizotinib
IND
Ibrutinib
Mantle cell lymphoma (MCL), 1L.
IND
Extension of indication to include treatment with Imbruvica in combination with bendamustine and rituximab (BR) of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for autologous stem cell transplantation
Lisocabtagene maraleucel
Loncastuximab tesirine
Pirtobrutinib
Polatuzumab vedotin
IND
Tafasitamab
Zamtocabtagene autoleucel
Zanubrutinib
IND
Antithrombotic medications
Dabigatran
G
Proteïne C
IND
Ravulizumab
IND
Asthma
Dupilumab
IND
Masitinib
Tezepelumab
Bacterial infections
Ceftobiprole
Ceftolozane / tazobactam
IND
Citric acid / lactic acid / potassium bitartrate
IND
Clindamycin
Dalbavancine
IND
Delafloxacin
IND
Durlobactam / sulbactam
Eravacycline
SER 109
Tebipenem
Bladder cancer
Avelumab
IND
Durvalumab
Neo-adjuvant durvalumab met chemotherapie en adjuvant durvalumab voor behandeling in patiënten met spier invasieve blaaskanker.
IND
Unresectable locally advanced or metastatic urothelial cancer in combination with tremelimumab and chemotherapy
IND
Enfortumab vedotin
Inbakicept
Nivolumab
IND
Bowel diseases
Etrolizumab
IND
Filgotinib
IND
Mirikizumab
Ozanimod
IND
Risankizumab
IND
Teduglutide
IND
Upadacitinib
Rinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
IND
Moderately to Severely Active Crohns disease
IND
Vedolizumab
IND
Brain cancer
Autologous glioma tumor cell lysates
Breast cancer
Abemaciclib
IND
Amcenestrant
Balixafortide
Neratinib
IND
Olaparib
IND
Paclitaxel
Palbociclib
Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery.
IND
Patients with HR+/HER2- invasive early breast cancer in combination with standard adjuvant endocrine therapy.
IND
Pembrolizumab
Extension of indication for Keytruda to include in combination with chemotherapy, treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express PD L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease.
IND
KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early‑stage triple‑negative breast cancer at high risk of recurrence.
IND
Sacituzumab govitecan
Tesetaxel
Trastuzumab deruxtecan
Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti HER2 based regimens.
Extension of indication for Enhertu to include treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.
IND
Patients with HER2 low, unresectable, and/or metastatic breast cancer previously treated with 1-2 prior lines of chemotherapy in the metastatic setting and has progressed on, and would no longer benefit from, endocrine therapy.
IND
Trastuzumab duocarmazine
Tucatinib
CLL
Acalabrutinib
Calquence as monotherapy is indicated for the treatment of adult patients with relapsed/refractory CLL (chronic lymphocytic leukemia).
Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
Duvelisib
Ibrutinib
IND
Pirtobrutinib
IND
Ublituximab
Zanubrutinib
Extension of indication to include treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL)
IND
Extension of indication to include treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one-prior anti-CD20-based therapy
IND
CML
Asciminib
COVID-19
APN01
Anakinra
IND
Baricitinib
IND
Casirivimab / imdevimab
IND
Casirivimab/imdevimab
Molnupiravir
PF-07321332 / ritonavir
Regdanvimab
IND
Remdesivir
Extension of indication to include adults who do not require invasive mechanical ventilation at start of treatment. • In adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).
IND
Treatment of paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) or other non-invasive ventilation at start of treatment
IND
Sotrovimab
Tixagevimab / cilgavimab
The prevention of COVID-19 in adults.
Extension of indication to include treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19, who do not require supplemental oxygen.
IND
Tocilizumab
IND
Cervical cancer
Cemiplimab
IND
Durvalumab
IND
Lifileucel
Colon cancer
Nivolumab
IND
Tegafur / gimeracil / oteracil
IND
Cystic fibrosis
Elexacaftor / tezacaftor / ivacaftor
Kaftrio is indicated in a combination regimen with ivacaftor 150mg tablets for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
IND
Ivacaftor
IND
Dementia
Aducanumab
Depression
Bupropion/dextromethorphan
Esketamine
IND
Zuranolone
Diabetes
Bexagliflozine
Dapagliflozine
IND
Dasiglucagon
Exenatide
IND
Finerenon
Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.
Extension of indication to include the treatment of chronic kidney disease (CKD) and for the prevention of cardiovascular (CV) events in adults with CKD (regardless of the stage of albuminuria) associated with type 2 diabetes
IND
Insulin lispro
G
Polyethylene glycol loxenatide
Sotagliflozine
IND
Teplizumab
Tirzepatide
Duchenne
Golodirsen
Vamorolone
Epilepsy
Brivaracetam
IND
Cannabidiol
IND
Cenobamaat
Fenfluramine
IND
Ganaxolone
Lacosamide
IND
Eye disorders
Aflibercept
IND
Avacincaptad pegol
Brolucizumab
IND
Faricimab
Treatment of neovascular (wet) age-related macular degeneration (nAMD).
Treatment of visual impairment due to diabetic macular oedema (DME).
Lenadogene nolparvovec
Pegcetacoplan
IND
Perfluorohexyloctane
Phentolamine
Ranibizumab
Wet age-related macular degeneration (AMD).
BS
Wet age-related macular degeneration (AMD).
BS
Treatment of neovascular age-related macular degeneration (AMD)
Reproxalap
Sepofarsen
Timrepigene emparvovec
Fungal infections
Ibrexafungerp
IND
Oteseconazole
Posaconazol
Extension of indication to include primary treatment of invasive aspergillosis in adults and adolescents from 13 years of age for Noxafil gastroresistant tablet and concentrate for solution for infusion.
IND
Extension of indication to include primary treatment of invasive aspergillosis in paediatric patients from 2 years of age weighing more than 40kg and adults for Noxafil gastroresistant tablet and concentrate for solution for infusion. Noxafil gastro-resistant tablets and solution are indicated for use in the treatment of the following fungal infections: Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products.
IND
Rezafungin
HIV
Atazanavir / cobicistat
Doravirine / lamivudine / tenofovirdisoproxil
IND
Fostemsavir
Lenacapavir
Raltegravir
BS
Head and neck cancer
Pembrolizumab
IND
Tislelizumab
IND
Headache
Atogepant
Dihydroergotamine
Eptinezumab
Lasmiditan
Meloxicam / rizatriptan
Rimegepant
Hemostasis promoting medication
Emicizumab
IND
Eptacog alfa (activated)
BS
Eptacog beta (activated)
Etranacogene dezaparvovec
FLT180a
Valoctocogene roxaparvovec
Indolent non-Hodgkin?s lymphoma
Axicabtagene ciloleucel
IND
Copanlisib
Hypericin
Lacutamab
Mosunetuzumab
Parsaclisib
Umbralisib
Infectious diseases other
Baloxavir marboxil
IND
Fluticasone propionate
Kidney cancer
Avelumab
IND
Cabozantinib
IND
Lenvatinib
IND
Pembrolizumab
Extension of indication for Keytruda to include in combination with lenvatinib first line treatment of adults with advanced renal cell carcinoma (RCC).
IND
Keytruda as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions.
IND
Tivozanib
IND
Lipid-lowering medications
Bempedoic acid
Evinacumab
Evolocumab
IND
Inclisiran
Liver cancer
Durvalumab
Durvalumab (+/- bevacizumab) in combinatie met TACE in patiënten met locoregionale HCC.
IND
Extension of indication to include IMFINZI in combination with tremelimumab for the treatment of adults with unresectable hepatocellular carcinoma (uHCC).
IND
Lenvatinib
IND
Pembrolizumab
IND
Pemigatinib
Tremelimumab
IND
Liver diseases
Maralixibat
IND
Obeticholic acid
Seladelpar
Lung cancer
Adagrasib
Amivantamab
Atezolizumab
Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and who do not have EGFR mutant or ALK‑positive NSCLC
IND
Extension of indication to include adjuvant treatment of non-small cell lung cancer (NSCLC) following resection and platinum-based chemotherapy for adult patients whose tumours have PD-L1 expression on ≥ 1% of tumour cells (TC) for Tecentriq as monotherapy
IND
Avelumab
IND
Capmatinib
Cemiplimab
Libtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC.
IND
Extension of indication to include LIBTAYO in combination with platinum‐based chemotherapy for the first-line treatment of adult patients with locally advanced NSCLC who are not candidates for definitive chemoradiation or metastatic NSCLC with no EGFR, ALK or ROS1 aberrations, independen of PD-L1 expression.
IND
Durvalumab
Extension of indication to include first-line treatment, with Imfinzi in combination with tremelimumab and platinum-based chemotherapy, of adults with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
IND
Non-small cell lung cancer (NSCLC) stage IV, in combination with chemo, 1L.
IND
1L advanced NSCLC
IND
Completely resected NSCLC
IND
Lokaal gevorderd, niet-resectabel NSCLC (stadium III)
IND
Limited stage small cell lung cancer (LS-SCLC) following concurrent platinum-based chemotherapy and radiation therapy in combination with Tremelimumab.
IND
Ensartinib
Lenvatinib
IND
Lorlatinib
IND
Lurbinectedin
Mobocertinib
Nivolumab
IND
OSE-2101
Osimertinib
IND
Pembrolizumab
IND
Pralsetinib
Selpercatinib
IND
Sintilimab
Sotorasib
Tepotinib
Tislelizumab
Toripalimab
Trastuzumab deruxtecan
IND
Tremelimumab
Trilaciclib
Lung diseases other
Ambrisentan
IND
Benralizumab
IND
Gefapixant
Mepolizumab
Extension of indication to include Eosinophilic Granulomatosis with Polyangiitis (EGPA) to Nucala
IND
Extension of indication to include Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) for Nucala (mepolizumab).
Pirfenidone
IND
Mesothelioma
Nivolumab
IND
Metabolic diseases
Arimoclomol
Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A gene
Avalglucosidase alfa
Bardoxolone Methyl
Betaine
G
Cipaglucosidase alfa / miglustat
Elamipretide
Fexapotide
Fezolinetant
Fosdenopterin
Hydrocortison
Leriglitazone
Levoketoconazole
Liraglutide
IND
Lonafarnib
Migalastat
IND
Octreotide
Olenasufligene relduparvovec
Olipudase alfa
Palovarotene
Pegunigalsidase alfa
Reloxaliase
Sapropterin
G
Somatrogon
Sparsentan
Multiple Myeloma
Belantamab mafodotin
IND
Carfilzomib
IND
Ciltacabtagene autoleucel
Daratumumab
Extension of indication to extend the existing therapeutic indication for daratumumab in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT).
IND
Extension of indication to extend the existing therapeutic indication for daratumumab in combination with lenalidomide and dexamethasone (Rd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
IND
Darzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis.
IND
In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy.
IND
Multipel myeloom frontline behandeling in combinatie met VRd voor patiënten die niet in aanmerking komen voor een ASCT.
IND
Smouldering multipel myeloom.
IND
Elranatamab
Idecabtagene vicleucel
Isatuximab
Sarclisa is indicated in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
IND
In Combination With Bortezomib, Lenalidomide and Dexamethasone (Isa VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant.
IND
Ixazomib
IND
Melphalan flufenamide
IND
Pomalidomide
IND
Selinexor
IND
Teclistimab
Thalidomide
G
Venetoclax
IND
Zevorcabtagene autoleucel
Multiple sclerosis
Dimethyl fumarate
Tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).
IND
Volwassenen met 'relapsing remitting' multipele sclerose (RRMS).
G
Volwassenen met 'relapsing remitting' multipele sclerose (RRMS).
G
Volwassenen met 'relapsing remitting' multipele sclerose (RRMS).
G
Diroximel fumarate
Ofatumumab
Teriflunomide
Aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis.
IND
Volwassenen met 'relapsing remitting' multipele sclerose (RRMS).
G
Ublituximab
Muscular diseases other
Amifampridine
G
Bidridistrogene xeboparvovec
Daxibotulinumtoxine A
Deoxythymidine/deoxycytidine
Di-deuterated ethyl linoleate
Efgartigimod
Ravulizumab
IND
Sugammadex
G
Myeloproliferative disorders
Momelotinib
Navitoclax
Ropeginterferon alfa-2b
Neuroendocrine cancer
Selumetinib
Surufatinib
Neurological disorders other
Cannabidiol gel/intradermaal
Clazosentan
Eculizumab
IND
Eladocagene exuparvovec
Inebilizumab
Remimazolam
Rozanolixizumab
Satralizumab
Tiratricol
Vutrisiran
Zilucoplan
Oncology other
Afamitresgene autoleucel
Dostarlimab
Durvalumab
IND
Efbemalenograstim alfa
Erdafitinib
Futibatinib
Glucarpidase
Infigratinib
Ivosidenib
IND
Jodium (131I) omburtamab
Lenvatinib
Extension of indication to include lenvatinib in combination with pembrolizumab for the treatment of adult patients with advanced endometrial carcinoma (EC) who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation
IND
Advanced or Recurrent Endometrial Cancer (1L) in combination with pembrolizumab.
IND
Lipegfilgrastim
IND
NY-ESO-1 autologous engineered TCR-T cells
Nivolumab
Opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy
IND
Extension of indication to include in combination with fluoropyrimidineand platinum-based combination chemotherapy the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) for OPDIVO.
IND
Pembrolizumab
Extension of indication to include pembrolizumab in combination with lenvatinib for the treatment of advanced endometrial carcinoma in adults who have disease progression following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation.
IND
Keytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD‑L1 with a CPS ≥ 1.
IND
Keytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 10.
IND
Keytruda as monotherapy is indicated for the treatment of the following MSI‑H or dMMR tumours in adults with: unresectable or metastatic colorectal cancer after previous fluoropyrimidine‑based combination therapy; advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum‑containing therapy in any setting and who are not candidates for curative surgery or radiation; unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.
IND
Selinexor
IND
Sodium thiosulfate
Tebentafusp
Other chronic immune diseases
Adrenaline
Arachis hypogaea (pinda) allergenen (pleister)
Avacopan
Avapritinib
IND
Baricitinib
Systemic lupus erythematosus
IND
Extension of indication to include treatment of severe alopecia areata in adult patients for Olumiant.
IND
Berotralstat
Budesonide modified released capsule
IND
Canakinumab
IND
Coacillium topical
Dupilumab
IND
FCR 001
Icatibant
G
Mavorixafor
OTL 103
RP-L201
Sizavaleucel
Sutimlimab
Voclosporin
Vonoprazan
Other hematology
Eltrombopag
IND
Zanubrutinib
Other medication for cardiovascular diseases
Allogenic immunomodulatory progenitor cells
Angiotensin II
Apabetalon
Dapagliflozine
IND
Emiplacel
Empagliflozine
IND
Etripamil
Fibrinogen / Thrombin
IND
Icosapent ethyl
Macitentan
IND
Macitentan / tadalafil
Mavacamten
Omecamtiv mecarbil
Rexlemestrocel-L
Rilonacept
Sotagliflozine
IND
Tadalafil
IND
Tafamidis
IND
Udenafil
Vericiguat
Other metabolism and Endocrinology
Abaloparatide
Burosumab
IND
Corifollitropin alfa
IND
Drospirenon / estetrol, monohydraat
Ospemifene
Semaglutide
Setmelanotide
IND
Other non-oncological hematological medications
Crizanlizumab
Daprodustat
Eculizumab
BS
Efgartigimod
Eptacog alfa
IND
Exagamglogene autotemcel
Horse anti-human T lymphocyte immunoglobulin
Luspatercept
IND
Mepolizumab
IND
Mitapivat
Pegcetacoplan
RP-L102
Ravulizumab
Behandeling van volwassen en pediatrische patiënten met een lichaamsgewicht van 10 kg of meer met paroxismale nachtelijke hemoglobinurie (PNH): - bij patiënten met hemolyse met klinische symptomen die wijzen op een hoge ziekteactiviteit. - bij patiënten die klinisch stabiel zijn nadat ze ten minste de afgelopen 6 maanden behandeld zijn met eculizumab
Uitbreiding van de behandeling naar pediatrische patiënten met een lichaamsgewicht van 10kg of meer met paroxismale nachtelijke hemoglobinurie (PNH):- bij patiënten met hemolyse met klinische symptomen die wijzen op een hoge ziekteactiviteit.- bij patiënten die klinisch stabiel zijn nadat ze ten minste de afgelopen 6 maanden behandeld zijn met eculizumab.
IND
UM171
Vadadustat
Voxelotor
Other psychiatry
Dexmedetomidine
Ovarian cancer
Dostarlimab
IND
Mirvetuximab soravtansine
Pain
Bupivacaine extended release
IND
Buprenorphine
IND
Fasinumab
Lidocaïne
SDN037
Parasitic infections
Lotilaner
Prostate cancer
Abiraterone
Geïndiceerd met prednison of prednisolon voor: - de behandeling van nieuw gediagnosticeerde hoog-risico gemetastaseerde hormoongevoelige prostaatkanker (mHSPC) bij volwassen mannen, in combinatie met androgeendeprivatietherapie (ADT). - de behandeling van gemetastaseerde castratieresistente prostaatkanker (mCRPC) bij volwassen mannen die asymptomatisch of licht symptomatisch zijn na falen van androgeendeprivatietherapie en voor wie behandeling met chemotherapie nog niet klinisch geïndiceerd is. - de behandeling van mCRPC bij volwassen mannen bij wie de ziekte progressief was tijdens of na een chemotherapieschema op basis van docetaxel.
G
Geïndiceerd met prednison of prednisolon voor: - de behandeling van nieuw gediagnosticeerde hoog-risico gemetastaseerde hormoongevoelige prostaatkanker (mHSPC) bij volwassen mannen, in combinatie met androgeendeprivatietherapie (ADT); - de behandeling van gemetastaseerde castratieresistente prostaatkanker (mCRPC) bij volwassen mannen die asymptomatisch of licht symptomatisch zijn na falen van androgeendeprivatietherapie en voor wie behandeling met chemotherapie nog niet klinisch geïndiceerd is; - de behandeling van mCRPC bij volwassen mannen bij wie de ziekte progressief was tijdens of na een chemotherapieschema op basis van docetaxel.
G
Darolutamide
Nubeqa is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.
Adult men with metastatic hormone senstive prostate cancer (mHSPC) in combination with docetaxel en ADT.
IND
Degarelix
IND
Leuprolide mesylate
Lutetium (177lu) vipivotide tetraxetan
Masitinib
Niraparib / abiraterone
Olaparib
Treatment in combination with abiraterone acetate in patients with metastatic Castration-resistant Prostate Cancer (mCRPC) who have not received prior chemotherapy or new hormonal agents (NHAs) for metastatic castration-resistant prostate cancer (mCRPC) (first-line setting).
IND
treatment of adults with metastatic castration resistant prostate cancer (mCRPC), with Lynparza in combination with abiraterone and prednisone or prednisolone
IND
Pembrolizumab
IND
Relugolix
Rheumatism
Anifrolumab
Cyclobenzaprine hydrochloride
Risankizumab
IND
Sarilumab
IND
Secukinumab
Extension of indication to include treatment of Juvenile Idiopathic Arthritis (Enthesitis Related Arthritis and Juvenile Psoriatic Arthritis) in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.
IND
Extension of indication to include treatment of Juvenile Idiopathic Arthritis (Enthesitis Related Arthritis and Juvenile Psoriatic Arthritis) in patients 2 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.
IND
Tofacitinib
IND
Upadacitinib
IND
SMA
Risdiplam
5q SMA in patients 2 months of age and older, with a clinical diagnosis of Type 1, Type 2 or Type 3 SMA or with one to four SMN2 copies.
Extension of indication to include treatment of patients below 2 months of age.
IND
Schizophrenia, psychosis, bipolar disorder
Lumateperone
Skin cancer
Darleukin fibromun
Lenvatinib
IND
Pembrolizumab
1L treatment with pembrolizumab for advanced melanoma, in combination with lenvatinib.
IND
Extension of indication to include the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, Stage IIC or stage III melanoma and to include the treatment of adolescents aged 12 years and older with advanced melanoma for Keytruda
IND
Relatlimab
Skin diseases
Abrocitinib
Beremagene geperpavec
Berkenschorsextract
Deucravacitinib
Difelikefalin
Dupilumab
Dupixent is geïndiceerd bij kinderen van 6 maanden tot 6 jaar met ernstige atopische dermatitis die in aanmerking komen voor systemische behandeling.
IND
Dupixent is geïndiceerd bij volwassenen voor de behandeling van Prurigo Nodularis die onvoldoende onder controle zijn met topische behandelingen, of wanneer deze behandelingen niet gepast zijn.
IND
Lebrikizumab
Ligelizumab
Regenerative Skin Tissue
Roflumilast topical
Ruxolitinib phosphate
Secukinumab
IND
Spesolimab
Tapinarof
Adult Plaque Psoriasis
Atopische dermatitis
Tirbanibulin
Tralokinumab
IND
Sleep disorders
Daridorexant
JZP-258
Natriumoxybaat controlled release
Pitolisant
Stem cell transplants
Brexucabtagene autoleucel
Inolimomab
Motixafortide
Omidubicel
Ruxolitinib
IND
Tabelecleucel
Tisagenlecleucel-T
IND
Treosulfan
IND
Stomach cancer
Nivolumab
IND
Ripretinib
Trastuzumab deruxtecan
IND
Zolbetuximab
Thyroid cancer
Cabozantinib
IND
Pralsetinib
Gavreto is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with Tyrosine Kinase inhibitors and not previously treated with a RET inhibitor.
Gavreto is indicated for the treatment of adults and pediatric patients 12 years of age and older with locally advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with Tyrosine kinase inhibitors and not previously treated with a RET inhibitor.
IND
Selpercatinib
1L treatment advanced or metastatic RET fusion-positive thyroid cancer (TC)
IND
1L treatment of adults and children >12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC).
IND
Unknown
Axicabtagene ciloleucel
IND
Dapagliflozine
IND
Diazoxide choline (controlled-release tablet)
Empagliflozine
IND
Levonorgestrel
G
Linzagolix
Lonapegsomatropin
Lumasiran
Mirabegron
IND
Olopatadine / mometasone
Osilodrostat
Pirfenidone
G
Relugolix
IND
Relugolix / estradiol / norethisteronen
Setmelanotide
Sirolimus
IND
Sofpironium bromide
Vosoritide
Viral infections other
Bizalimogene ralaplasmid
Bulevirtide
Elbasvir / grazoprevir
IND
Glecaprevir / pibrentasvir
IND
Lonafarnib
IND
Maribavir
Nirsevimab
Remdesivir
IND
Sofosbuvir / velpatasvir
IND
Sofosbuvir / velpatasvir / voxilaprevi
IND
Tecovirimat
Naar boven
National Health Care Institute
Login
Understanding of expected market entry
of innovative medicines
Service
Contact
Downloads
Export
About this site
Copyright
Privacy
Cookies
Toegankelijkheid
Kwetsbaarheid melden
Over de Horizonscan
About the Horizon Scan
Nederlands
English